Literature DB >> 1166982

Interaction of chronic daily warfarin therapy and rifampin.

R A O'Reilly.   

Abstract

To evaluate the interaction between the antibiotic rifampin and the anticoagulant warfarin during chronic therapy, eight normal subjects were given daily doses of warfarin for 21 days to achieve therapeutic hypoprothrombinemia. Daily blood samples were analyzed for one-stage prothrombin activity and for warfarin content spectrophotometrically and chromatographically. One month later, the same warfarin dose was repeated plus rifampin, 600 mg a day orally. For the last 10 days of every experiment, there was a highly significant lessening of both the hypoprothrombinemic effect (P less than 0.001) and the blood levels of warfarin (P less than 0.001). No significant difference in the warfarin levels was found between the spectrophotometric and chromatographic methods. It is concluded that rifampin markedly decreases the hypoprothrombinemic effect of warfarin during long-term therapy by enhancing its elimination from plasma. This conclusion was reinforced by finding increased amounts of warfarin metabolites in urine and stool.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1166982     DOI: 10.7326/0003-4819-83-4-506

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

Review 1.  Anticoagulants in older patients. A safety perspective.

Authors:  R J Beyth; C S Landefeld
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

2.  Drug interactions: a primer for the gastroenterologist.

Authors:  Christina Teeter Doligalski; Angela Tong Logan; Andrew Silverman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-06

3.  Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring.

Authors:  Paul K L Chin; Murray L Barclay; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.

Authors:  S M MacLeod; E M Sellers
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Acute cardiac failure during treatment with digitoxin--an interaction with rifampicin.

Authors:  G Boman; K Eliasson; I Odar-Cederlöf
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

7.  The effect of rifampicin on norethisterone pharmacokinetics.

Authors:  D J Back; A M Breckenridge; F Crawford; M MacIver; M L Orme; B K Park; P H Rowe; E Smith
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

Review 8.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Influence of rifampin on fleroxacin pharmacokinetics.

Authors:  J Schrenzel; P Dayer; T Leemann; E Weidekamm; R Portmann; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.